Groesbeck Investment Management Corp NJ Invests $206,000 in Edwards Lifesciences Co. (NYSE:EW)

Groesbeck Investment Management Corp NJ acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, HoldingsChannel reports. The fund acquired 2,700 shares of the medical research company’s stock, valued at approximately $206,000.

A number of other large investors have also recently made changes to their positions in EW. Advisors Asset Management Inc. grew its holdings in Edwards Lifesciences by 0.3% during the 1st quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock valued at $5,127,000 after buying an additional 117 shares during the last quarter. Apollon Wealth Management LLC grew its holdings in Edwards Lifesciences by 1.0% during the 1st quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock valued at $1,033,000 after buying an additional 119 shares during the last quarter. Geller Advisors LLC grew its holdings in Edwards Lifesciences by 6.5% during the 1st quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock valued at $231,000 after buying an additional 120 shares during the last quarter. Legacy Wealth Asset Management LLC boosted its holdings in shares of Edwards Lifesciences by 0.8% during the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock worth $1,293,000 after purchasing an additional 134 shares during the last quarter. Finally, KCM Investment Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 2.7% during the first quarter. KCM Investment Advisors LLC now owns 5,392 shares of the medical research company’s stock worth $635,000 after purchasing an additional 142 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the transaction, the vice president now directly owns 39,503 shares of the company’s stock, valued at $3,390,542.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the sale, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the sale, the vice president now directly owns 39,503 shares in the company, valued at $3,390,542.49. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 over the last three months. 1.29% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on EW. Wells Fargo & Company upgraded Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective on the stock in a report on Friday, February 2nd. Citigroup raised their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Oppenheimer raised their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Stifel Nicolaus raised their price objective on Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a report on Wednesday, February 7th. Finally, Truist Financial raised their price objective on Edwards Lifesciences from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, December 22nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $91.73.

Edwards Lifesciences Stock Down 0.4 %

NYSE:EW traded down $0.32 during mid-day trading on Thursday, hitting $86.92. The company had a trading volume of 1,310,404 shares, compared to its average volume of 3,839,839. The business has a fifty day simple moving average of $90.12 and a 200-day simple moving average of $78.14. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12. The firm has a market capitalization of $52.32 billion, a price-to-earnings ratio of 37.93, a PEG ratio of 4.46 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same period last year, the company posted $0.64 earnings per share. The firm’s revenue was up 13.3% compared to the same quarter last year. Equities analysts forecast that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.